|
|
Office Locations:
|
2727 N. Harwood St., Suite 200
Dallas, TX 75201
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Remeditex Ventures' mission is to develop early stage biomedical science and make Texas a preferred location for biotechnology companies, venture capitalists, and entrepreneurs. The objectives of Remeditex are to: Accelerate the pace of commercialization of biomedical research in Texas; Help create and support a thriving biotechnology industry in Texas; Attract biotech venture capital to Texas; and Achieve significant returns to support the next generation of promising science. Remeditex is looking to partner with the universities and health systems in Texas diligently performing world-class research to gain a better understanding of the mechanisms of disease and more effective diagnostics, therapeutics, or prevention strategies. The firm is interested in translational research projects with highly defensible intellectual property and focused on diseases with significant unmet clinical needs and on potentially disruptive technologies.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
